Treatment options for multidrug-resistant nonfermenters

David Felipe Briceño; John P. Quinn; Mara Virginia Villegas

doi:10.1586/eri.09.125

Treatment options for multidrug-resistant nonfermenters

David Felipe Briceño, John P. Quinn, Mara Virginia Villegas

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

Multidrug-resistant nonfermenters are a worldwide threat. Pseudomonas aeruginosa and Acinetobacter baumannii have been associated with high mortality and treatment failures. In addition, therapeutic options are increasingly narrowed, mainly due to widespread resistance in these pathogens and a shortage of new antimicrobial compounds. Hence, old, potent but toxic antibiotics such as the polymyxins are re-emerging as therapeutic options. Maximizing pharmacokinetics/pharmacodynamics with existing agents is also a worthwhile approach to explore. This problem exemplifies the critical need for new drug development for multidrug-resistant Gram-negative microorganisms.

Original language	English (US)
Pages (from-to)	303-315
Number of pages	13
Journal	Expert Review of Anti-Infective Therapy
Volume	8
Issue number	3
DOIs	https://doi.org/10.1586/eri.09.125
State	Published - Mar 2010
Externally published	Yes

Keywords

Carbapenems
Combination therapy
Nonfermenters
Pharmacodynamics
Pharmacokinetics
Polymyxins
Resistance mechanisms

ASJC Scopus subject areas

Microbiology
Microbiology (medical)
Virology
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1586/eri.09.125

Cite this

@article{c7f13e21d1be44fba8ea2c73d994b460,

title = "Treatment options for multidrug-resistant nonfermenters",

abstract = "Multidrug-resistant nonfermenters are a worldwide threat. Pseudomonas aeruginosa and Acinetobacter baumannii have been associated with high mortality and treatment failures. In addition, therapeutic options are increasingly narrowed, mainly due to widespread resistance in these pathogens and a shortage of new antimicrobial compounds. Hence, old, potent but toxic antibiotics such as the polymyxins are re-emerging as therapeutic options. Maximizing pharmacokinetics/pharmacodynamics with existing agents is also a worthwhile approach to explore. This problem exemplifies the critical need for new drug development for multidrug-resistant Gram-negative microorganisms.",

keywords = "Carbapenems, Combination therapy, Nonfermenters, Pharmacodynamics, Pharmacokinetics, Polymyxins, Resistance mechanisms",

author = "Brice{\~n}o, {David Felipe} and Quinn, {John P.} and Villegas, {Mara Virginia}",

year = "2010",

month = mar,

doi = "10.1586/eri.09.125",

language = "English (US)",

volume = "8",

pages = "303--315",

journal = "Expert Review of Anti-Infective Therapy",

issn = "1478-7210",

publisher = "Expert Reviews Ltd.",

number = "3",

}

TY - JOUR

T1 - Treatment options for multidrug-resistant nonfermenters

AU - Briceño, David Felipe

AU - Quinn, John P.

AU - Villegas, Mara Virginia

PY - 2010/3

Y1 - 2010/3

N2 - Multidrug-resistant nonfermenters are a worldwide threat. Pseudomonas aeruginosa and Acinetobacter baumannii have been associated with high mortality and treatment failures. In addition, therapeutic options are increasingly narrowed, mainly due to widespread resistance in these pathogens and a shortage of new antimicrobial compounds. Hence, old, potent but toxic antibiotics such as the polymyxins are re-emerging as therapeutic options. Maximizing pharmacokinetics/pharmacodynamics with existing agents is also a worthwhile approach to explore. This problem exemplifies the critical need for new drug development for multidrug-resistant Gram-negative microorganisms.

AB - Multidrug-resistant nonfermenters are a worldwide threat. Pseudomonas aeruginosa and Acinetobacter baumannii have been associated with high mortality and treatment failures. In addition, therapeutic options are increasingly narrowed, mainly due to widespread resistance in these pathogens and a shortage of new antimicrobial compounds. Hence, old, potent but toxic antibiotics such as the polymyxins are re-emerging as therapeutic options. Maximizing pharmacokinetics/pharmacodynamics with existing agents is also a worthwhile approach to explore. This problem exemplifies the critical need for new drug development for multidrug-resistant Gram-negative microorganisms.

KW - Carbapenems

KW - Combination therapy

KW - Nonfermenters

KW - Pharmacodynamics

KW - Pharmacokinetics

KW - Polymyxins

KW - Resistance mechanisms

UR - http://www.scopus.com/inward/record.url?scp=77649322077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649322077&partnerID=8YFLogxK

U2 - 10.1586/eri.09.125

DO - 10.1586/eri.09.125

M3 - Review article

C2 - 20192684

AN - SCOPUS:77649322077

SN - 1478-7210

VL - 8

SP - 303

EP - 315

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

IS - 3

ER -

Treatment options for multidrug-resistant nonfermenters

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this